Department of Ophthalmology, Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, 639 Zhizaoju Road, Shanghai 200011, China.
Exp Eye Res. 2013 Feb;107:65-73. doi: 10.1016/j.exer.2012.11.014. Epub 2012 Dec 5.
Thyroid-associated ophthalmopathy (TAO) is characterised by increased volume of the orbital contents involving adipose tissue, but the factors responsible for stimulation of orbital adipogenesis remain uncertain. Previous studies have shown that insulin-like growth factor 1 (IGF-1) is increased in the orbital fatty connective tissues of patients with TAO. The present study was conducted to investigate the effects of IGF-1 on orbital adipose-derived stromal cells (OADSCs) derived from TAO patients and to identify the signalling mechanisms involved. Our results showed that IGF-1 significantly promoted the cell proliferation and lipid accumulation of TAO OADSCs. The mRNA expression of adipogenic markers (adiponectin, leptin, adipocyte fatty acid binding protein [AP2] and fatty acid synthase [FAS]) was increased in TAO cultures treated with IGF-1. Further research demonstrated that the protein levels of peroxisome proliferator-activated receptor-γ (PPARγ) were up-regulated when OADSCs were treated with IGF-1. We also found that the inhibition of either IGF-1 receptor (IGF-1R) or phosphoinositide 3-kinase (PI3K) activity decreased the levels of IGF-1-stimulated mRNA encoding adiponectin, leptin, AP2, and FAS, as well as PPARγ protein levels. Moreover, the expression of phosphorylated Akt (p-Akt) protein in TAO cells was up-regulated by IGF-1, while a specific PI3K inhibitor (LY294002) or an antibody of IGF-1R blocked this effect. These results indicate that IGF-1 is a pro-proliferative and pro-adipogenic factor in TAO OADSCs. IGF-1 enhances the adipogenesis of TAO OADSCs by up-regulation of PPARγ via the activation of the IGF-1R and PI3K pathways, suggesting that the blocking of IGF-1R or inhibition of PI3K signalling might be a potential novel therapeutic approach to TAO.
甲状腺相关眼病(TAO)的特征是眶内容物体积增加,包括脂肪组织,但刺激眼眶脂肪生成的因素仍不确定。先前的研究表明,胰岛素样生长因子 1(IGF-1)在 TAO 患者的眶脂肪结缔组织中增加。本研究旨在探讨 IGF-1 对 TAO 患者来源的眼眶脂肪基质细胞(OADSCs)的影响,并确定涉及的信号机制。我们的结果表明,IGF-1 可显著促进 TAO-OADSCs 的细胞增殖和脂质积累。IGF-1 处理的 TAO 培养物中,脂肪生成标志物(脂联素、瘦素、脂肪细胞脂肪酸结合蛋白[AP2]和脂肪酸合酶[FAS])的 mRNA 表达增加。进一步的研究表明,当 OADSCs 用 IGF-1 处理时,过氧化物酶体增殖物激活受体-γ(PPARγ)的蛋白水平上调。我们还发现,IGF-1 受体(IGF-1R)或磷脂酰肌醇 3-激酶(PI3K)活性的抑制降低了 IGF-1 刺激的脂联素、瘦素、AP2 和 FAS 的 mRNA 编码水平,以及 PPARγ 蛋白水平。此外,IGF-1 可上调 TAO 细胞中磷酸化 Akt(p-Akt)蛋白的表达,而特定的 PI3K 抑制剂(LY294002)或 IGF-1R 抗体可阻断这种作用。这些结果表明,IGF-1 是 TAO-OADSCs 的促增殖和促脂肪生成因子。IGF-1 通过激活 IGF-1R 和 PI3K 途径上调 PPARγ,增强 TAO-OADSCs 的脂肪生成,表明阻断 IGF-1R 或抑制 PI3K 信号可能是治疗 TAO 的一种新的潜在治疗方法。